Biogen (BIIB) Guides FY12; Sees Buying Back an Added $500M in Stock
Tweet
Share
E-mailGet Alerts BIIB Hot Sheet
Price: $222.67 --0%
Revenue Growth %: +4.3%
Financial Fact:
Total cost and expenses: 1.53B
Today's EPS Names:
VIVO, PMCB, PLCE, More
Revenue Growth %: +4.3%
Financial Fact:
Total cost and expenses: 1.53B
Today's EPS Names:
VIVO, PMCB, PLCE, More
Join SI Premium – FREE
Biogen (Nasdaq: BIIB) sees FY12 adj-EPS above $6.15, which compares to the Street estimate of $6.19.
Expecting to buyback an additional $500 million in common shares.
Expecting to buyback an additional $500 million in common shares.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Stoke, Biogen to present 4-year zorevunersen data at epilepsy congress
- Five Below (FIVE) Tops Q2 EPS by 35c, Beats on Revenue; Offers Q3 Revenue Guidance
- Netskope, Inc. (NTSK) Tops Q2 EPS by 4c, Offers Guidance
Create E-mail Alert Related Categories
Guidance, Stock BuybacksSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
